{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:05:46Z","timestamp":1771232746613,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2020,4,24]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Lower extremity artery disease (LEAD) is a marker of a more advanced atherosclerotic process\noften affecting multiple vascular beds beyond the lower limbs, with a consequent increased risk for\nall-cause and cardiovascular mortality. Antithrombotic therapy is the cornerstone of management of\nthese patients to prevent ischaemic cardiovascular and limb events and death. In patients with symptomatic\nLEAD, the efficacy of aspirin has been established long ago for the prevention of cardiovascular\nevents. In the current guidelines, clopidogrel may be preferred over aspirin following its incremental\nability to prevent cardiovascular events, while ticagrelor is not superior to clopidogrel in reducing cardiovascular\noutcomes. Dual antiplatelet therapy (DAPT, aspirin with clopidogrel) is currently recommended\nfor at least 1 month after endovascular interventions irrespective of the stent type. Antiplatelet\nmonotherapy is recommended after infra-inguinal bypass surgery, and DAPT may be considered in\nbelow-the-knee bypass with a prosthetic graft. In symptomatic LEAD, the addition of anticoagulant\n(vitamin K antagonists) to antiplatelet therapy increased the risk of major and life-threatening bleeding\nwithout benefit regarding cardiovascular outcomes. In a recent trial, low dose of direct oral anticoagulant\nrivaroxaban plus aspirin showed promising results, not only to reduce death and major cardiovascular\nevents, but also major limb events including amputation. Yet, this option should be considered especially\nin very high risk patients, after considering also the bleeding risk. Despite all the evidence accumulated\nsince &gt;40 years, many patients with LEAD remain undertreated and deserve close attention and\nimplementation of guidelines advocating the use of antithrombotic therapies, tailored according to their\nlevel of risk.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161117666190206230516","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T23:42:01Z","timestamp":1587771721000},"page":"215-222","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antithrombotic Therapy in Lower Extremity Artery Disease"],"prefix":"10.2174","volume":"18","author":[{"given":"Mislav","family":"Vrsalovic","sequence":"first","affiliation":[{"name":"University of Zagreb, School of Medicine, Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Dupuytren University Hospital Centre, Limoges, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T23:42:02Z","timestamp":1587771722000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169725\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161117666190206230516","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}